Personalised versus non-individualised case-based CME: A randomised pilot study
Herman Stoevelaar(Barnes-Jewish Hospital), Martin C. Michel(Johannes Gutenberg University Mainz), Bertrand Tombal(Cliniques Universitaires Saint-Luc), Johan Stranne(European Association of Urology), Thomas Zilli(University of Geneva), Nicky Helsen(Besins Healthcare (Belgium)), Amit Bahl(At Bristol), Jessa Yperman(Exmar (Belgium)), Nele Michels(European Council), Luc Van Ruysevelt, Jaan Toelen(Health and Human Development (2HD) Research Network), Mark Speakman(Taunton & Somerset NHS Foundation Trust), Louis Smets, Frank Van der Aa(KU Leuven)
Cited by 1
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
XVI. International Union of Pharmacology Recommendations for the Nomenclature of Neuropeptide Y, Peptide YY, and Pancreatic Polypeptide Receptors
|Pharmacological Reviews|1998|893
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)
|The Lancet|2012|864
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
|New England Journal of Medicine|2020|442